Literature DB >> 21552020

Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.

José Willegaignon1, Marcelo Sapienza, Carla Ono, Tomoco Watanabe, Maria Inês Guimarães, Ricardo Gutterres, Maria Helena Marechal, Carlos Buchpiguel.   

Abstract

PURPOSES: To evaluate the dosimetric effect of outpatient radioiodine therapy for thyroid cancer in members of a patient's family and their living environment, when using iodine-131 doses reaching 7.4 GBq. The following parameters were thus defined: (a) whole-body radiation doses to caregivers, (b) the production of contaminated solid waste, and (c) radiation potential and surface contamination within patients' living quarters.
METHODS: In total, 100 patients were treated on an outpatient basis, taking into consideration their acceptable living conditions, interests, and willingness to comply with medical and radiation safety guidelines. Both the caregivers and the radiation dose potentiality inside patients' residences were monitored by using thermoluminescent dosimeters. Surface contamination and contaminated solid wastes were identified and measured with a Geiger-Müller detector.
RESULTS: A total of 90 monitored individuals received a mean dose of 0.27 (±0.28) mSv, and the maximum dose registered was 1.6 mSv. The mean value for the potential dose within all living quarters was 0.31 (±0.34) mSv, and the mean value per monitored surface was 5.58 Bq/cm(2) for all the 1659 points measured. The overall production of contaminated solid wastes was at a low level, being about 3 times less than the exemption level indicated by the International Atomic Energy Agency.
CONCLUSIONS: This study indicates that the treatment of thyroid cancer by applying radioiodine activities up to 7.4 GBq, on an outpatient basis, is a safe procedure, especially when supervised by qualified professionals. This alternative therapy should be a topic for careful discussion considering the high potential for reducing costs in healthcare and improving patient acceptance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21552020     DOI: 10.1097/RLU.0b013e3182184fa0

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient 131I Therapy for Differentiated Thyroid Cancer.

Authors:  Cristiane J Gomes-Lima; Di Wu; Pejman H Kharazi; Gauri J Khojekar; Matthew D Ringel; Richard J Vetter; Gary Bloom; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Thyroid       Date:  2017-12       Impact factor: 6.568

2.  HSA-MnO2-131I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma.

Authors:  Ziyu Yan; Xuemei Zhang; Yifan Liu; Yiming Shen; Ning Li; Qiang Jia; Yanhui Ji; Peitao Zhang; Li Zhao; Zhaowei Meng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

3.  Do Current Radiation Safety Guidelines allow the Safe Release of a Thyroid Cancer Patient after High-dose Radioiodine Therapy? An Indian Perspective.

Authors:  Subhash Chand Kheruka; Nilesh Shankar; Manish Ora; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2021-06-21

4.  Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles.

Authors:  Shijie Li; Daqi Zhang; Shihou Sheng; Hui Sun
Journal:  Int J Nanomedicine       Date:  2017-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.